This is a competitive solicitation for a firm-fixed-price contract to examine the health benefits of GLP-1 receptor agonists versus DPP-4 inhibitors for alcohol and substance use disorders in people living with HIV, using VA electronic health record data. The anticipated period of performance runs from August 7, 2026 through August 6, 2027, with three additional 12-month option periods. No specific budget amount is stated, and the place of performance is not specified. The evaluation will consider technical capability, past performance, and price, with non-price factors significantly more important than price. This requirement is full and open with no set-aside restrictions under NAICS 541690 (size standard $19M).